$123.56
0.52% yesterday
Nasdaq, Jun 27, 10:13 pm CET
ISIN
US7599161095
Symbol
RGEN

Repligen Corporation Stock price

$123.56
+1.02 0.83% 1M
-21.98 15.10% 6M
-20.38 14.16% YTD
-3.03 2.39% 1Y
-41.31 25.06% 3Y
+4.47 3.75% 5Y
+82.25 199.10% 10Y
+121.41 5,646.98% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.65 0.52%
ISIN
US7599161095
Symbol
RGEN
Sector
Industry

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$6.8b
Net debt
$-167.6m
Cash
$697.2m
Shares outstanding
56.2m
Valuation (TTM | estimate)
P/E
negative | 72.16
P/S
8.64 | 9.60
EV/Sales
8.43 | 9.37
EV/FCF
56.58
P/B
3.50
Financial Health
Equity Ratio
69.72%
Return on Equity
-1.29%
ROCE
0.76%
ROIC
1.03%
Debt/Equity
0.27
Financials (TTM | estimate)
Revenue
$803.6m | $722.8m
EBITDA
$113.6m | $140.7m
EBIT
$20.6m
Net Income
$-19.7m | $96.2m
Free Cash Flow
$119.7m
Growth (TTM | estimate)
Revenue
32.28% | 13.93%
EBITDA
57.67% | 42.67%
EBIT
739.35%
Net Income
-231.99% | 477.11%
Free Cash Flow
9.38%
Margin (TTM | estimate)
Gross
51.03%
EBITDA
14.13% | 19.46%
EBIT
2.56%
Net
-2.45% | 13.31%
Free Cash Flow
14.90%
More
EPS
$-0.35
FCF per Share
$2.13
Short interest
8.14%
Employees
1.78k
Rev per Employee
$360.00k
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Repligen Corporation forecast:

19x Buy
76%
6x Hold
24%

Analyst Opinions

25 Analysts have issued a Repligen Corporation forecast:

Buy
76%
Hold
24%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
804 804
32% 32%
100%
- Direct Costs 394 394
16% 16%
49%
410 410
53% 53%
51%
- Selling and Administrative Expenses 331 331
49% 49%
41%
- Research and Development Expense 55 55
32% 32%
7%
114 114
58% 58%
14%
- Depreciation and Amortization 93 93
34% 34%
12%
EBIT (Operating Income) EBIT 21 21
739% 739%
3%
Net Profit -20 -20
232% 232%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
Business Wire
12 days ago
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the com...
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company's progress in advancing our sustainabil...
Neutral
GlobeNewsWire
about 2 months ago
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today